BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
See today's BioWorld
Home
» Threshold Pharmaceuticals' Phase III Drills Down on Sarcoma
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Threshold Pharmaceuticals' Phase III Drills Down on Sarcoma
Oct. 3, 2011
By
Catherine Shaffer
No Comments
Threshold Pharmaceuticals Inc. is wasting no time launching a Phase III randomized trial of its sarcoma drug, TH-302, following a successful end-of-Phase-II meeting with the FDA, resulting in a special protocol assessment.
BioWorld